KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Receivables (2016 - 2022)

TherapeuticsMD (TXMD) has disclosed Receivables for 13 consecutive years, with $32.2 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Receivables fell 14.02% year-over-year to $32.2 million, compared with a TTM value of $32.2 million through Sep 2022, down 14.02%, and an annual FY2021 reading of $36.2 million, up 11.72% over the prior year.
  • Receivables was $32.2 million for Q3 2022 at TherapeuticsMD, down from $45.8 million in the prior quarter.
  • Across five years, Receivables topped out at $45.8 million in Q2 2022 and bottomed at $5.1 million in Q1 2018.
  • Average Receivables over 5 years is $24.1 million, with a median of $24.1 million recorded in 2020.
  • The sharpest move saw Receivables surged 226.75% in 2019, then decreased 14.02% in 2022.
  • Year by year, Receivables stood at $11.1 million in 2018, then skyrocketed by 120.5% to $24.4 million in 2019, then skyrocketed by 32.74% to $32.4 million in 2020, then rose by 11.72% to $36.2 million in 2021, then dropped by 11.11% to $32.2 million in 2022.
  • Business Quant data shows Receivables for TXMD at $32.2 million in Q3 2022, $45.8 million in Q2 2022, and $35.4 million in Q1 2022.